etaracizumab   

GtoPdb Ligand ID: 6596

Synonyms: etaratuzumab | hLM60 | MEDI-522
Compound class: Antibody
Comment: Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
No information available.
Summary of Clinical Use
Etaracizumab is a humanized investigational monoclonal antibody for the treatment of metastatic melanoma, prostate cancer, ovarian cancer and various other types of cancer [1]. Click here to view records held with ClinicalTrials.gov which are assessing this antibody.
Mechanism Of Action and Pharmacodynamic Effects
Etaracizumab targets integrin αVβ3 (vitronectin receptor) [3]. Vitronectin is a serum and extracellular matrix glycoprotein involved in cell adhesion and migration, and may be involved in tumour malignancy [2]. Interaction between vitronectin and integrin αVβ3 anchors cells to the extracellular matrix. Etaracizumab inhibits this interaction and has antitumor, antiangiogenic, and antiosteolytic activities [3].